在基于人群的癌症登记中填补雌激素受体(ER)状态:一项敏感性分析
该研究针对监测、流行病学和最终结果(SEER)项目中乳腺癌ER状态缺失率早期高达25%的问题,开发了预测均值匹配多重填补方法,可在随机缺失(MAR)或非随机缺失假设下填补ER状态,并应用于1992-2012年SEER乳腺癌数据。研究发现两种假设下推断存在一些差异但幅度通常较小,对于主要关注的分析类型,作者建议在MAR假设下填补SEER乳腺癌生物标志物。
要点
- SEER登记中ER状态早期缺失率高达25%,既往校正方法依赖随机缺失(MAR)假设。
- 作者开发预测均值匹配多重填补法,可在MAR或非随机缺失假设下填补ER状态。
- 两种假设下推断差异存在但幅度通常较小,作者建议主要分析在MAR假设下填补。
核心结论
- 在MAR与非随机缺失假设下推断存在一些差异,但差异幅度通常较小;对于通常主要关注的分析类型,作者建议在MAR假设下填补SEER乳腺癌生物标志物。
研究设计与样本
- 研究开发了预测均值匹配多重填补程序,可在MAR或非随机缺失假设下填补缺失的ER状态,并应用于SEER乳腺癌数据(1992-2012年)。
- 填补程序利用SEER登记中丰富协变量的预测能力,同时允许研究偏离MAR假设的影响。
主要发现
- ER状态自1992年起被收集,但历史上报告不佳,早期缺失率高达25%。
- 在两种假设下推断存在一些差异,但差异幅度通常较小。
关键数值与推荐
- SEER乳腺癌数据年份范围为1992-2012年。
- ER状态缺失率早期高达25%。
临床怎么用
- 作者建议:对于通常主要关注的分析类型,在MAR假设下填补SEER乳腺癌生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast cancers are clinically heterogeneous based on tumor markers. The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program provides baseline data on these tumor markers for reporting cancer burden and trends over time in the US general population. These tumor markers, however, are often prone to missing observations. In particular, estrogen receptor (ER) status, a key biomarker in the study of breast cancer, has been collected since 1992 but historically was not well-reported, with missingness rates as high as 25% in early years. Previous methods used to correct estimates of breast cancer incidence or ER-related odds or prevalence ratios for unknown ER status have relied on a missing-at-random (MAR) assumption. In this paper, we explore the sensitivity of these key estimates to departures from MAR. We develop a predictive mean matching procedure that can be used to multiply impute missing ER status under either an MAR or a missing not at random assumption and apply it to the SEER breast cancer data (1992-2012). The imputation procedure uses the predictive power of the rich set of covariates available in the SEER registry while also allowing us to investigate the impact of departures from MAR. We find some differences in inference under the two assumptions, although the magnitude of differences tends to be small. For the types of analyses typically of primary interest, we recommend imputing SEER breast cancer biomarkers under an MAR assumption, given the small apparent differences under MAR and missing not at random assumptions. Copyright © 2016 John Wiley & Sons, Ltd.
引用
- Andridge R, Noone AM, Howlader N, et al. Imputing estrogen receptor (ER) status in a population-based cancer registry: a sensitivity analysis. Stat Med. 2016. PMID: 27921315. doi:10.1002/sim.7193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。